Caladrius Biosciences, Inc (NASDAQ:CLBS) CEO David J. Mazzo, PhD sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The New Jersey-based late-stage therapeutics development company's current product candidates include three developmental treatments for cardiovascular diseases.
Caladrius Biosciences CEO outlines key objectives for its cardiovascular programs in 2020
Quick facts: Caladrius Biosciences Inc
Price: 2.6 USD
Market Cap: $40.44 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE